A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Ozanimod (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms TRUE NORTH
- Sponsors Celgene International SARL; Receptos
- 27 Jul 2017 According to a celgene corporation media release, company anticipates to complete the enrollment in second half of 2017.
- 09 May 2017 Planned End Date changed from 30 Sep 2018 to 31 Dec 2018.
- 09 May 2017 Planned primary completion date changed from 1 Sep 2018 to 30 Sep 2018.